- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) Responses occurred across subgroups, with greater response
Clinical Responses Reported across Patient Subgroups with Adaptimmune s Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.